- cafead Sep 16, 2024 at 10:12: AM
via Bayer is targeting a broader use of Nubeqa in metastatic hormone-sensitive prostate (mHSPC) cancer with a combination free of chemotherapy.
Bayer plans to seek the FDA’s blessing for Nubeqa plus androgen deprivation therapy (ADT) in mHSPC after the phase 3 ARANOTE trial showed that the combination led to a statistically significant 46% reduction in the risk of progression or death compared with ADT alone.
article source
Bayer plans to seek the FDA’s blessing for Nubeqa plus androgen deprivation therapy (ADT) in mHSPC after the phase 3 ARANOTE trial showed that the combination led to a statistically significant 46% reduction in the risk of progression or death compared with ADT alone.
article source